Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma
Clinical trial NCT04609293 · UNKNOWN
Trial details
- NCT number
- NCT04609293
- Sponsor
- Peking University First Hospital
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2020-10-20
- Primary completion
- 2023-09-07
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.